|
References
1Grahame R, Scott JT. Clinical survey of 354 patients with gout. Ann Rheum Dis 1970;29:461-468.
2Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol. 2000; 27(4):1045-50.
3Chen YC, Chang HW. Clincial manifestations of young gout patients in Taiwan. Journal of Rheumatology, R.O.C. 2002; 16(1~2):29-37.
4Patterson DH. The cause of Down’s syndrome. Sci AM. 1987;257, 42-49.
5Rehder H. Pathology of trisomy 21, with particular reference to persistent common atrioventricular canal of the heart. In "Trisomy 21: An International Symposium"(. Burgio GR, Fraccaro M, Teipolo L , Wolf U. Eds.), 1981, pp. 57-73. dpringer-Verlag, Berlin.
6Fong C, Brodeur GM. Down’s syndrome and leukemia: Epidemiology, genetics, cytogenetics and mechanism of leukogenesis. Cancer Genet. Cytogenet. 28, 55-76.
7Tam CF , Walford RL. Alteration in cyclic nucleotides and cyclase-specific activities in T lymphocytes of aging in normal humans and patients with Dwon’s syndrome. J. Immunol 1980;125:1665-1670.
8Caffey J. In "Paediatric X-Ray Diagnosis," 1978 Vol 1, 7th Ed.,00155-157. Yearbook Medical Publishers Inc., Chicago.
9Sinet PM. Metabolism of oxygen derivatives in Dowm’s syndrome.Annals New York Academy of Sciences. 1982;396:83-94.
10Sichitiu S, Sinet PM, Frezal J. 1974. Surdosage dosage de la forme dimetrique de lindophenoloxydase dans la trisomie 21,secondaire au surdosage genique Humangenetik 23:65-72
11Sinet PM, Allard D, Lejeune J, Jerome H. 1974 .Augmentation dactivite de la superoxide dismutase erythrocytaire dans la trisomie pour le chromosome 21.C.R.Acad sci. Paris 278:3267-3270.
12Crosti N, Serra A, Rigo A, viglino P. 1976. Dosage effect of SOD-A gene In 21-trisomic cells. Hum.Genet.1976;31:197-202.
13Guilles L, Ferradini C, Foods J, Pucheault J, Allard D, Sinet PM, Jerome H. The estimation of red blood cell superoxide dismutase activity by pulse radiolysis in normal and trisomic cells. Hum Genet.31, 197-202.
14Tan YH, Tischfield J, Ruddle FH. The linkage of the genes for the human interferon-induced antiviral protein and indophenol oxidase B traits to chromosome 21. J Exp Med 1973;137:317-330.
15Zitnanova I, Korytar P, Aruoma OI, Sustrova M, Garaiova I, Muchova J, Kalnovicova T, Pueschel S, Durackova Z. Uric acid and allantoin levels in Down syndrome: antioxidant and oxidative stress mechanisms? Clin Chim Acta. 2004; 341(1-2):139-46.
16Pelsman A, Hoyo-Vadillo C, Gudasheva TA, Seredenin SB, Ostrovskaya RU, Busciglio J. GVS-111 prevents oxidative damage and apoptosis in normal and Down's syndrome human cortical neurons. Int J Dev Neurosci. 2003; 21(3):117-24.
17Fuller RW, Luce MW, Mertz ET. Serum uric acid in mongolism. Science 1962;137:868-9.
18Kaufman JM, O'Brien WM. Hyperuricemia in mongolism. N Engl J Med. 1967;276(17):953-6.
19Pant SS, Moser HW, Krane SM. Hyperuricemia in Down’s syndrome. J Clin Endocrinol Metab. 1968;28(4):472-8.
20Kucera J. Hyperuricemia in Down’s syndrome(etiology, significance, and possibilities of its modification). Cesk Pediatr. 1976;31(6):316-9.
21Okabe H, Mizuguchi M. Secondary hyperuricemia in Down’s syndrome. Nippon Rinsho. 2003;61 Suppl 1:318-22.
22Cayla J, Rondier J, Auscher C, Perreau C, De Gery A. Goutte et mongolisme. A propos d`une observation. Reutisme 1974;41:203-7
23Nishida Y, Akaoka I, Nishizawa T, Maruki M, Aikawa T, Mitamura T, Yokohari R, Horiuchi Y. A case of gouty arthritis associated with Down’s syndrome. J Ment Defic Res. 1976;20(4):277-83.
24Ciompi ML, Bazzichi LM, Bertolucci D, Mazzoni MR, Barbieri P, Mencacci S, Macchia D, Mariani G. Uric acid metabolism in two patients with coexistent Down’s syndrome and gout.. Clin Rheumatol. 1984;3(2):229-33.
25Dacre JE, Huskisson EC. Arthritis in Down`s syndrome . Ann Rheum Dis 1988;47:254-5.
26Kamatani N, Yamanaka H, Tokokawa S, Kashiwazaki S, Higurashi M. Down’s syndrome with coexistence gout: report of six patients and possible reasons for the scarcity of descriptions of this association. Ann Rheum Dis. 1996;55(9):649-50.
27Gregory L, Williams R, Thompson E. Leukocyte function in Down`s syndrome and acute leukaemia . Lancet 1972;i:1359 .
28Binz PA, Muller M, Hoogland C, Zimmermann C, Pasquarello C, Corthals G, Sanchez JC, Hochstrasser DF, Appel RD. The molecular scanner: concept and developments. Curr Opin Biotechnol. 2004 Feb;15(1):17-23.
29Sanches JC, Corthals GL, Hochstrasser DF. Biomedical Applications of Proteomics. Wiley-VCH , 2004.
30Righetti PG, Castagna A, Antonucci F, et al. proteiomic analysis in the clinical chemistry laboratory: myth or reality? Clin Chim Acta 2005;357:123-39.
31Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, YU T-F. Preliminary criteria for the classification of the acute ahritis of primary gout.Arthritis Rheum 1977;20:895-900
32Wilson JM, Young AB, Kelley WN. Hypoxanthine-guanine phosphoribosyltransferase deficiency. The molecular basis of the clinical syndromes. N Engl J Med. 1983;309(15):900-10.
33Puukka R, Puukka M, Perkkila L, Kouvalainen. Levels of some purine metabolizing enzymes in lymphocytes from patients with Down’s syndrome. Biochemical Medicine and metabolic biology 1986;36:45-50.
34Zitnanova I, Korytar P, Aruoma OI, Sustrova M, Garaiova I, Muchova J, Kalnovicova T, Pueschel S, Durackova Z. Uric acid and allantoin levels in Down syndrome: antioxidant and oxidative stress mechanisms?
Clin Chim Acta. 2004;341(1-2):139-46.
35Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, Yankner BA. Gene regulation and DNA damage in the ageing human brain.
Nature. 2004;24;429(6994):883-91
36Jacomelli G, Micheli V, Peruzzi L, Notarantonio L, Cerboni B, Sestini S, Pompucci G. Simple non-radiochemical HPLC-linked method for screening for purine metabolism disorders using dried blood spot. Clin Chim Acta. 2002 ;324(1-2):135-9.
37Yamada Y, Goto H, Suzumori K, Adachi R, Ogasawara N. Molecular analysis of five independent Japanese mutant genes responsible for hypoxanthine guanine phosphoribosyltransferase (HPRT) deficiency. Hum Genet. 1992; 90(4):379-84.
38Hikita M, Hosoya T, Ichida K, Okabe H, Saji M, Ohno I, Kuriyama S, Tomonari H, Hayashi F, Onouchi K, Fujimori S, Yamaoka N, Sakuma R. Partial deficiency of hypoxanthine-guanine phosphoribosyltransferase manifesting as acute renal damage. Intern Med. 1998; 37(11):945-9.
39Wang PW, Chang WN, Lu CH, Chao D, Schrag C, Pan TL. New insights into the pathological mechanisms of cerebrotendinous xanthomatosis in the Taiwanese using genomic and proteomic tool. Proteomics, in press (2006).
40Pusch W, Kostrzewa M. Application of MALDI-TOF mass spectrometry in screening and diagnostic research. Curr Pharm Des. 2005; 11: 2577-2591.
41Kenneth H Yu, Rustgi Anil K, Blair Ian A. Characterization of Proteins in Human Pancreatic Cancer Serum Using Differential Gel Electrophoresis and Tandem Mass Spectrometry. Journal of Proteome Research 2005, 4:1742- 1751
42Gregoric A, Rabelink GM, Vokac NK, Varda NM, Zagradisnik B. Eighteen-year follow-up of a partial hypoxanthine phosphoribosyltransferase deficiency and a new mutation. Pediatr Nephrol. 2005; 20(9): 1346-8.
43Tarak S, Patrick O J, Majed D, Ari MS.Childhood hyperuricemia and acute renal failure resulting from a missense mutation in the HPRT gene. Am J Med Genet. 2002; 108: 219-22.
44de Haan JB, Susil B, Pritchard M, Kola I. An altered antioxidant balance occurs in Down syndrome fetal organs : implications for the“gene dosage effect”hypothesis. J Neural Transm Suppl. 2003; 67: 67-83.
45Lim SK. Consequences of haemolysis without haptoglobin. Redox Rep. 2001; 6(6): 375-8.
46Balestrieri M, Cigliano L, Simone ML, Dale B, Abrescia P. Haptoglobin inhibits lecithin-cholesterol acyltransferase in human ovarian follicular fluid. Mol Reprod Dev. 2001; 59(2): 186-91.
47Lacko AG, Hayes JD, McConathy WJ, lacko I. Redheendran R. Lecithin: cholesterol acyltransferase in Down’s syndrome. Clin Chim Acta 1983;132:133-41.
48Mooradian AD, Haas MJ, Wong NC. Transcriptional control of apolipoprotein A-I gene expression in diabetes. Diabetes. 2004;53(3):513-20.
49Hargrove GM, Junco A, Wong NCW: Hormonal regulation of apolipoprotein AI. J Mol Endocrinol22 :103 –111,1999
50Terkeltaub RA, Sklar LA, Mueller H. Neutrophil activation by inflammatory microcrystals of monosodium urate monohydrate utilizes pertussis toxin-insensitive and -sensitive pathways.
J Immunol. 1990;144(7):2719-24.
51Bomalaski JS, Baker DG, Brophy LM, Clark MA. Monosodium urate crystals stimulate phospholipase A2 enzyme activities and the synthesis of a phospholipase A2-activating protein.
J Immunol. 1990;145(10):3391-7.
52Gaudry M, Gilbert C, Barabe F, Poubelle PE, Naccache PH. Activation of Lyn is a common element of the stimulation of human neutrophils by soluble and particulate agonists.
Blood. 1995;86(9):3567-74.
53Liu R, O'Connell M, Johnson K, Pritzker K, Mackman N, Terkeltaub R. Extracellular signal-regulated kinase 1/extracellular signal-regulated kinase 2 mitogen-activated protein kinase signaling and activation of activator protein 1 and nuclear factor kappaB transcription factors play central roles in interleukin-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells.
Arthritis Rheum. 2000;43(5):1145-55.
54Terkeltaub R, Zachariae C, Santoro D, Martin J, Peveri P, Matsushima K. Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystal-induced inflammation. Arthritis Rheum. 1991;34(7):894-903.
55Schiltz C, Liote F, Prudhommeaux F, Meunier A, Champy R, Callebert J, Bardin T. Monosodium urate monohydrate crystal-induced inflammation in vivo: quantitative histomorphometric analysis of cellular events. Arthritis Rheum. 2002;46(6):1643-50.
56Tramontini NL, Kuipers PJ, Huber CM, Murphy K, Naylor KB, Broady AJ, Kilgore KS. Modulation of leukocyte recruitment and IL-8 expression by the membrane attack complex of complement (C5b-9) in a rabbit model of antigen-induced arthritis.
Inflammation. 2002;26(6):311-9.
57Webster ME, Maling HM, Zweig MH, Williams MA, Anderson W Jr. Urate crystal induced inflammation in the rat: evidence for the combined actions of kinins, histamine and components of complement. Immunol Commun. 1972;1(2):185-98.
58Jaramillo M, Godbout M, Naccache PH, Olivier M. Signaling events involved in macrophage chemokine expression in response to monosodium urate crystals. J Biol Chem. 2004;279(50):52797-805
59Nishimura A, Akahoshi T, Takahashi M, Takagishi K, Itoman M, Kondo H, Takahashi Y, Yokoi K, Mukaida N, Matsushima K. Attenuation of monosodium urate crystal-induced arthritis in rabbits by a neutralizing antibody against interleukin-8. J Leukoc Biol. 1997;62(4):444-9.
60Rouleau P, Vandal K, Ryckman C, Poubelle PE, Boivin A, Talbot M, Tessier PA. The calcium-binding protein S100A12 induces neutrophil adhesion, migration, and release from bone marrow in mouse at concentrations similar to those found in human inflammatory arthritis. Clin Immunol. 2003;107(1):46-54.
61Ryckman C, McColl SR, Vandal K, de Medicis R, Lussier A, Poubelle PE, Tessier PA. Role of S100A8 and S100A9 in neutrophil recruitment in response to monosodium urate monohydrate crystals in the air-pouch model of acute gouty arthritis. Arthritis Rheum. 2003;48(8):2310-20.
62Liote F, Prudhommeaux F, Schiltz C, Champy R, Herbelin A, Ortiz-Bravo E, Bardin T. Inhibition and prevention of monosodium urate monohydrate crystal-induced acute inflammation in vivo by transforming growth factor beta1. Arthritis Rheum. 1996;39(7):1192-8.
63Huynh ML, Fadok VA, Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest. 2002;109(1):41-50.
64Murakami Y, Akahoshi T, Kawai S, Inoue M, Kitasato H. Antiinflammatory effect of retrovirally transfected interleukin-10 on monosodium urate monohydrate crystal-induced acute inflammation in murine air pouches. Arthritis Rheum. 2002;46(9):2504-13.
65Akahoshi T, Namai R, Murakami Y, Watanabe M, Matsui T, Nishimura A, Kitasato H, Kameya T, Kondo H. Rapid induction of peroxisome proliferator-activated receptor gamma expression in human monocytes by monosodium urate monohydrate crystals.
Arthritis Rheum. 2003;48(1):231-9.
66Terkeltaub R, Curtiss LK, Tenner AJ, Ginsberg MH. Lipoproteins containing apoprotein B are a major regulator of neutrophil responses to monosodium urate crystals. J Clin Invest. 1984;73(6):1719-30.
67Terkeltaub RA, Dyer CA, Martin J, Curtiss LK. Apolipoprotein (apo) E inhibits the capacity of monosodium urate crystals to stimulate neutrophils. Characterization of intraarticular apo E and demonstration of apo E binding to urate crystals in vivo.J Clin Invest. 1991;87(1):20-6.
68Ortiz-Bravo E, Sieck MS, Schumacher HR Jr. Changes in the proteins coating monosodium urate crystals during active and subsiding inflammation. Immunogold studies of synovial fluid from patients with gout and of fluid obtained using the rat subcutaneous air pouch model. Arthritis Rheum. 1993;36(9):1274-85.
69Ciompi ML, Bazzichi LM, Bertolucci D, Mazzoni MR, Barbieri P, Mencacci S, Macchia D, Mariani G. Uric acid metabolism in two patients with coexistent Down's syndrome and gout. Clin Rheumatol. 1984 Jun;3:229-33
70Yagame M. Specificity of IgA antibodies in sera from patients with IgA nephropathy. Nippon Jinzo Gakkai Shi. 1992; 34(4): 353-60.
71Hrncir Z, Krupar V, Bradna P, Tichy M. Clinical importance of changes in antibody immunity in gout. Vnitr Lek. 1989; 35(1): 52-7.
|